Valuation: Immuno-Biological Laboratories Co., Ltd.

Market Cap 9.34B 59.57M 53.2M 49.15M 44.54M 83.32M 5.66B 84.7M 591M 234M 2.96B 224M 219M P/E 2025
18x
P/E 2026 38x
Enterprise Value 8.53B 54.39M 48.57M 44.87M 40.66M 76.07M 5.16B 77.33M 540M 214M 2.71B 204M 200M EV / Sales 2025
3.97x
EV / Sales 2026 11.6x
Free-Float
82.46%
Yield 2025 *
-
Yield 2026 0.45%
23-05-12 Immuno-Biological Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
23-02-05 An unknown buyer agreed to acquire unknown minority stake in CURED Co., Ltd. from Immuno-Biological Laboratories Co., Ltd. CI
19-12-19 An undisclosed buyer acquired 26.32% stake in Cell Remover Co., Ltd. from Immuno-Biological Laboratories Co., Ltd.. CI
19-03-28 CURED Co., Ltd. announced that it has received ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
19-02-26 CURED Co., Ltd. announced that it expects to receive ¥598.4 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
18-11-14 Neo Silk Cosmetics Co., Ltd. announced that it has received ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
18-11-04 Neo Silk Cosmetics Co., Ltd announced that it expects to receive ¥40 million in funding from Immuno-Biological Laboratories Co., Ltd. CI
17-06-27 Transgenic Inc. Enters into Joint Research Agreement with Immuno-Biological Laboratories Co. Ltd CI
16-12-19 Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥1.4 billion in funding from Whiz Partners Inc. CI
16-11-30 Immuno-Biological Laboratories Co., Ltd. announced that it expects to receive ¥1.39 billion in funding from Whiz Partners Inc. CI
16-05-10 CURED Co., Ltd. announced that it has received ¥159.6 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd. CI
16-04-19 CURED announced that it expects to receive ¥159.6 million in funding from Trans Genic Inc. and Immuno-Biological Laboratories Co., Ltd. CI
16-03-30 Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it has received ¥100 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd. CI
1 day+2.19%
1 week-1.82%
Current month-14.51%
1 month-12.17%
3 months+4.81%
6 months-26.58%
Current year-45.91%
1 week 960
Extreme 960
1,062
1 month 960
Extreme 960
1,219
Current year 888
Extreme 888
2,025
1 year 464
Extreme 464
3,820
3 years 356
Extreme 356
3,820
5 years 285
Extreme 285
3,820
10 years 285
Extreme 285
3,820
Manager TitleAgeSince
President 82 1982-08-31
Director of Finance/CFO 64 2008-03-31
Chief Administrative Officer 65 2004-05-31
Director TitleAgeSince
Director/Board Member 82 1982-08-31
Director/Board Member 64 2008-05-31
Director/Board Member 65 2001-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+2.19%-1.82%+114.44%+126.27% 59.57M
-2.54%+1.31%+54.27%+117.14% 1,135B
-1.42%+3.23%+38.56%+74.05% 635B
+0.16%+0.08%+25.29%+96.64% 505B
-0.31%+3.09%+44.14%+64.55% 378B
-1.34%-0.47%+66.04%+40.18% 358B
-0.68%+2.65%+22.98%+49.15% 295B
-1.20%+3.04%+2.33%+21.60% 266B
-1.79%+1.57%+50.56%+61.40% 237B
-0.73%-0.10%+29.02%+99.06% 193B
Average -0.77%+0.98%+44.76%+75.00% 400.37B
Weighted average by Cap. -1.35%+1.63%+41.03%+80.33%

Financials

2025 2026
Net sales 969M 6.18M 5.52M 5.1M 4.62M 8.64M 587M 8.79M 61.35M 24.29M 307M 23.19M 22.7M 1B 6.4M 5.72M 5.28M 4.79M 8.96M 608M 9.1M 63.56M 25.16M 318M 24.03M 23.52M
Net income 249M 1.59M 1.42M 1.31M 1.19M 2.22M 151M 2.26M 15.76M 6.24M 78.98M 5.96M 5.83M 329M 2.1M 1.87M 1.73M 1.57M 2.93M 199M 2.98M 20.83M 8.25M 104M 7.87M 7.71M
Net Debt -621M -3.96M -3.54M -3.27M -2.96M -5.54M -376M -5.63M -39.32M -15.57M -197M -14.86M -14.55M -813M -5.18M -4.63M -4.28M -3.88M -7.25M -492M -7.37M -51.47M -20.38M -258M -19.46M -19.04M
Projected Income Statement - Annual - Immuno-Biological Laboratories Co., Ltd.
Logo Immuno-Biological Laboratories Co., Ltd.
Immuno-Biological Laboratories Co., Ltd. is a Japan-based company engaged in the research, development, manufacture and sales of pharmaceutical products and quasi-drugs. The Company operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
Employees
54
Date Price Change Volume
26-10-26 JP¥1,025.00 +2.19% 51,900
26-10-23 JP¥1,003.00 +0.50% 113,300
26-10-22 JP¥998.00 -3.39% 121,800
26-10-21 JP¥1,033.00 +2.79% 47,600
26-10-20 JP¥1,005.00 -3.74% 93,000

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Immuno-Biological Laboratories Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4570 Stock